Off-Label Use of Atypical Antipsychotics: An Update
Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review (1 of 2)
A variety of validated assessment instruments are used to measure outcomes of treatment with atypical antipsychotics, both in practice and in clinical studies. Remission rates and changes in symptom severity are reported. Response rates are defined as the proportion of participants achieving an a priori-specified degree of improvement on a rating scale.
For dementia, outcomes are often assessed with the Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD), the Brief Psychiatric Rating Scale (BPRS), and the Neuropsychiatric Inventory Scale (NPI). For major depressive disorder, the Hamilton Depression Rating Scale (HAM-D) and the Montgomery-Asberg Depression Rating Score (MADRS) are common choices. For obsessive-compulsive disorder, the Yale-Brown Obsessive Compulsive Scale (YBOCS) is used. For eating disorders, the body mass index (BMI) is used for treatment monitoring. Generalized anxiety disorder is evaluated with the Hamilton Anxiety Rating Scale (HAM-A).
Keywords: assessment BEHAVE-AD | atypical antipsychotics | BMI | BPRS | dementia | eating disorders | generalized anxiety disorder | HAM-A | HAM-D | MADRS | major depressive disorder | MDD | NPI | obsessive-compulsive disorder | OCD | off-label | second generation | YBOCS | antipsychotics
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.